Skip to main content

Advertisement

SpringerLink
Log in

Survival Analysis of Contralateral Prophylactic Mastectomy: A Question of Selection Bias

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Rates of contralateral prophylactic mastectomy (CPM) in women with breast cancer have increased, but most studies fail to show a survival benefit. We evaluated survival among CPM patients compared to patients undergoing single mastectomy (SM).

Methods

The Surveillance, Epidemiology, and End Results database was used to identify unilateral breast cancer patients who underwent mastectomy with/without CPM from 1998 to 2010. Case-control analysis was performed with CPM cases matched to SM controls on the basis of age group, race/ethnicity, extent of surgery, grade, T classification, N classification, estrogen receptor status, and propensity score. Survival analyses included Kaplan–Meier curves and univariate and multivariate proportional hazard models to determine factors associated with disease-specific (DSS) and overall survival (OS).

Results

A total of 26,526 CPM patients were identified. On multivariate regression analysis, increasing age, greater extent of surgery, increasing T and N stage, African American race, Hispanic ethnicity, poorly differentiated grade, and estrogen receptor negativity were associated with increased risk of death. CPM was associated with improved DSS (HR 0.86, 95 % CI 0.79–0.93) and even greater OS (HR 0.76, 95 % CI 0.71–0.81) compared with SM. Contralateral breast cancer (CBC) occurred in 1.6 % of women in the cohort. Removing CBC cases from analysis had little impact on CPM DSS (HR 0.86, 95 % CI 0.79–0.93) and OS (0.77, 95 % CI 0.72–0.82) suggesting that prevention of CBC by CPM does not explain the observed survival benefit.

Conclusions

CPM rates continue to rise. The improved DSS and OS observed with CPM support selection bias. Prospective trials are needed to determine cohorts of patients most likely to benefit from CPM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Buzdar A. Breast cancer survival on the rise: report of MD Anderson experience. Reported in advance of the 2010 Breast Cancer Symposium in Washington, DC. Available at: http://www.mdanderson.org/publications/conquest/issues/2011-spring/breast-cancer-survival.html. Accessed 18 Dec 2013.

  3. Lichter AS, Lippman ME, Danforth DN Jr, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 1992;10:976–83.

    PubMed  CAS  Google Scholar 

  4. Gomez SL, Lichtensztajn D, Kurian AW, et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. J Clin Oncol. 2010;28:e155–7.

    Article  PubMed  Google Scholar 

  5. Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 1984;71:711–4.

    Article  PubMed  CAS  Google Scholar 

  6. Rosen PP, Groshen S, Kinne DW, et al. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery. 1989;106:904–10.

    PubMed  CAS  Google Scholar 

  7. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol. 2003;56:1038–45.

    Article  Google Scholar 

  8. Healey E, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characeteristics and impact on prognosis. J Clin Oncol. 1993;11:1545–52.

    PubMed  CAS  Google Scholar 

  9. Vaittinen P, Hemmenki K. Risk factors and age–incidence relationships for contralateral breast cancer. Int J Cancer. 2000;88:998–1002.

    Article  PubMed  CAS  Google Scholar 

  10. Peralta EA, Ellenhorn JD, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180:439–45.

    Article  PubMed  CAS  Google Scholar 

  11. McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal history and family history of breast cancer. J Clin Oncol. 2001;19:3938–43.

    PubMed  CAS  Google Scholar 

  12. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a Cancer Research Network project. J Clin Oncol. 2005;23:4275–86.

    Article  PubMed  Google Scholar 

  13. Van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93:287–92.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.

    Article  PubMed  Google Scholar 

  15. Tuttle TM, Jarosek S Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27:1362–7.

    Article  PubMed  Google Scholar 

  16. Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol. 2012;19:2600–6.

    Article  PubMed  Google Scholar 

  17. Yao K, Winchester DJ, Czechura T, Huo D. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002. Breast Cancer Res Treat. 2013;142:465–76.

    Article  PubMed  Google Scholar 

  18. Surveillance, Epidemiology, and End Results. Available at: http://seer.cancer.gov. Accessed 15 Sep 2013.

  19. Surveillance, Epidemiology, and End Results (SEER) Program. Research data, 1973–2010. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. Available at: http://seer.cancer.gov. Accessed 15 Sep 2013.

  20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer;2010.

    Google Scholar 

  21. Brewster AM, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118:5637–43.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26:734–53.

    Article  PubMed  Google Scholar 

  23. Parsons LS. Reducing bias in a propensity score marched-pair sample using greedy matching techniques group (paper 214-26). In: Proceedings of the 26th Annual SAS Users Group International Conference, April 2001.

  24. Narod SA. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat. 2011;128:581–3.

    Article  PubMed  CAS  Google Scholar 

  25. Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. Br Med J. 2014;348:1–11.

    Article  Google Scholar 

  26. Evans DGR, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140:135–42.

    Article  PubMed  CAS  Google Scholar 

  27. Tracy MS, Rosenberg SM, Dominici L, Partridge AH. Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research. Breast Cancer Res Treat. 2013;140:447–52.

    Article  PubMed  Google Scholar 

  28. McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy: trends in use from 1995–2005. Cancer. 2009;115:5404–12.

    Article  PubMed  Google Scholar 

  29. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97:439–48.

    Article  PubMed  Google Scholar 

  30. Newman L. Disparities in breast cancer. Curr Probl Cancer. 2007;31:134–56.

    Article  PubMed  Google Scholar 

  31. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49–56.

    Article  PubMed  Google Scholar 

  32. Newman L, Mason J, Cote D, et al. Afrincan-American ethnicity, socioeconomic status and breast cancer survival. Cancer. 2002;94:2844–54.

    Article  PubMed  Google Scholar 

  33. Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology study. J Natl Cancer Inst. 2008;100:32–40.

    Article  PubMed  CAS  Google Scholar 

  34. Broet P, Rochefordiere A, Schall SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995;13:1578–83.

    PubMed  CAS  Google Scholar 

  35. Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110:189–97.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Baum M, Budzar AU. Cuzick J, et al; ATAC Trialists Group. Anastrazole alone or in combination with tamoxifen versus tamoxfien alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131–9.

    Article  PubMed  CAS  Google Scholar 

  37. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Ajuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.

    Article  PubMed  CAS  Google Scholar 

  38. Nichols HB, Gonzalez AB, Lacey JV, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29:1564–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17:2702–9.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Bedrosian I, Hu C, Chang G. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102:401–9.

    Article  PubMed  Google Scholar 

  41. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;(11):CD002748.

    PubMed  Google Scholar 

Download references

Disclosure

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA, USA

    Laura Kruper MD, MSCE & Rondi M. Kauffmann MD, MPH

  2. Department of Information Sciences, City of Hope National Medical Center, Duarte, CA, USA

    David D. Smith PhD & Rebecca A. Nelson PhD

Authors
  1. Laura Kruper MD, MSCE
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rondi M. Kauffmann MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David D. Smith PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rebecca A. Nelson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura Kruper MD, MSCE.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kruper, L., Kauffmann, R.M., Smith, D.D. et al. Survival Analysis of Contralateral Prophylactic Mastectomy: A Question of Selection Bias. Ann Surg Oncol 21, 3448–3456 (2014). https://doi.org/10.1245/s10434-014-3930-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-3930-0

Keywords

Search

Navigation